Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Uxin (UXIN) Research & Development (2017 - 2025)

Uxin filings provide 9 years of Research & Development readings, the most recent being -$477000.0 for Q4 2025.

  • On a quarterly basis, Research & Development fell 45.43% to -$477000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was -$435.3 million, a 47.91% increase, with the full-year FY2025 number at $1.8 million, up 191.44% from a year prior.
  • Research & Development hit -$477000.0 in Q4 2025 for Uxin, up from -$434.0 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $18.0 in Q2 2024 to a low of -$2.2 billion in Q1 2021.
  • Median Research & Development over the past 5 years was -$454000.0 (2025), compared with a mean of -$325.0 million.
  • The widest YoY moves for Research & Development: up 100.0% in 2024, down 61487381.59% in 2024.
  • Uxin's Research & Development stood at -$1.8 billion in 2021, then surged by 100.0% to -$1368.0 in 2022, then changed by 0.0% to -$1368.0 in 2023, then plummeted by 23876.61% to -$328000.0 in 2024, then plummeted by 45.43% to -$477000.0 in 2025.
  • The last three reported values for Research & Development were -$477000.0 (Q4 2025), -$434.0 million (Q3 2025), and -$431000.0 (Q2 2025) per Business Quant data.